RxDoctor Payments Data

Jenelle Miller, MD

Hematology & Oncology · Indianapolis, INNPI 1114926060

Payments from drug & device makers

$4,716in general payments, 2019–2025

Across 203 payments — averaging $23.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$371
  • Sanofi$278
  • Pharmacyclics LLC, An Abbvie Company$249
  • Novartis$248
  • Lilly USA, LLC$242
  • Tersera Therapeutics LLC$207
  • plus $3K from 50 others

What the payments were for

  • Food & beverage$4,49595%
  • Education$2215%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,716 in reported general payments places this provider in the 40th percentile of 224 hematology & oncology providers in Indiana.

See all hematology & oncology providers in Indiana

Medicare billing

Part B allowed, 2024
$1,222,752
Medicare patients
594
Services billed
68,427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide43$722,992
ImbruvicaIbrutinib44$566,750
VerzenioAbemaciclib27$405,294
OnuregAzacitidine11$281,514
PomalystPomalidomide12$253,597
ScemblixAsciminib Hydrochloride11$236,384
Pazopanib Hcl12$123,138
EliquisApixaban75$62,834
XareltoRivaroxaban44$51,614
LinzessLinaclotide22$12,048
Anastrozole488$11,451
Tamoxifen Citrate101$2,191
Hydroxyurea52$1,910
Imatinib Mesylate14$1,282
Letrozole62$1,205

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$144$722,99243 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$249$566,75044 claims
E.r. Squibb & Sons, L.L.C.Onureg, Pomalyst$88$535,11123 claims
Lilly USA, LLCVerzenio$242$405,29427 claims
NovartisScemblix$248$236,38411 claims
PfizerEliquis$100$62,83475 claims
Johnson & JohnsonXarelto$207$51,61444 claims
AbbVieLinzess$160$12,04822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 224 hematology & oncology providers in Indiana.

Other hematology & oncology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →